Keywords: Merck KGaA, Erbitux, Colorectal cancer, ECCO/ESMO

Merck KGaA hit by disappointing Erbitux results from COIN study

Article | 24 September 2009

Print This

German drug major Merck KGaA suffered a setback on September 23, on the news that one of its leading products, the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in